Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: Results of a single-institute Phase I study

Journal of Radiation Research

Volumn 55, Issue 6, 2014, Pages 1171-1177

  Miki, Yoshitaka ^a   Maeda, Kiyoshi ^a   Hosono, Masako ^a   Nagahara, Hisashi ^a   Hirakawa, Kosei ^a   Shimatani, Yasuhiko ^a   Tsutsumi, Shinichi ^a   Miki, Yukio ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bevacizumab; Capecitabine; Chemoradiotherapy; Rectal cancer

Indexed keywords

CHEMORADIOTHERAPY; CHEMOTHERAPY; ONCOLOGY; RADIOTHERAPY; TOXICITY;

BEVACIZUMAB; CAPECITABINE; CLINICAL TRIAL; DOSE LEVELS; LEVEL-1; LOCALLY ADVANCED RECTAL CANCERS; PELVIC RADIOTHERAPY; PHASE I; PREOPERATIVE CHEMORADIOTHERAPY; RECTAL CANCER;

DISEASES;

BEVACIZUMAB; CAPECITABINE; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ADENOCARCINOMA; ADJUVANT THERAPY; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE COMPLICATIONS; RADIATION DOSE; RECTAL NEOPLASMS;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS;

EID: 84942053028     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1093/jrr/rru063     Document Type: Article

References (34)

1. Kapiteijin E, Maijnen C A M, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
2. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001;358:1291-304.
3. Bosset JF, Collette L, Callais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23.
4. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-7.
5. Kusters M, Beets GL, Van De Velde C J H et al. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Annals of Surg 2009;249:229-35.
6. Uehara K, Hiramatsu K, Maeda A et al. Neoadjuvant oxalipalatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 phase II trial: Jpn J Clin Oncol 2013;43:964-71.
7. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD9203. J Clin Oncol 2006;24:4620-5.
8. Sauer R, Fietkau R, Wittekind C et al. Adjuvant vs neoadjvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis 2003;5:406-15.
9. Roh MS, Colangelo LH, O'Connell MJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124-30.
10. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.
11. Cassidy J, Twelves C A Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-75.
12. Das P, Lin EH, Bhatia S et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched pair analysis. Int J Radiat Oncol Biol Phys 2006;66:1378-83.
13. Koukourakis GV, Zacharias G, Tsalafoutas J et al. Capecitabine for locally advanced and metastatic colorectal cancer: a review. World J Gastrointest Oncol 2010;2:311-21.
14. Saif MW, Hashmi S, Zelterman D et al. Capecitabine vs continuous infusion 5FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis 2008;32:139-45.
15. Chang AK, Wong AO, Jenken DA. Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer-is it equivalent to 5-FU infusion plus leucovorin and radiotherapy? Int J Radiat Oncol Biol Phys 2010;76:1413-9.
16. Welch S, Spithoff RB, Rumble RB et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010;21:1152-62.
17. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009;100:1704-19.
18. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007;26:3661-78.
19. Crane CH, Eng C, Feig BW et al. Phase II trial of neoadjubant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010;76:824-30.
20. Koukourakis MI, Giatromanolaki A, Tsoutsou P et al. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HYPOARC) for rectal cancer: a phase II study. Int J Radiat Oncol Biol Phys 2011;80:492-8.
21. Velenik V, Ocvrik J, Music M et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol 2011;6:105-12.
22. Gasparini G, Torino F, Ueno T et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012;15:141-50.
23. Resch G, De Vries A, Ofner D et al. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer - a two stage phase II clinical trial. Radiother Oncol 2012;102:10-3.
24. Okubo M, Nishimura Y, Nakamatsu K et al. Radiation treatment planning using positron emission and computed tomography for lung and pharyngeal cancers: a multiple-threshold method for [18F]fluoro-2-deoxyglucose activity. Int J Radiat Oncol Biol Phys 2010;77:350-6.
25. Dunst J, Reese T, Sutter T et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002;20:3983-91.
26. Ngan S Y K, Michael M, Mackay J et al. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 2004;91:1019-24.
27. Ben-Josef E. Capecitabine and radiotherapy as neoadjvant treatment for rectal cancer. Am J Clin Oncol 2007;30:649-55.
28. Clavien PA, Barkun J, De Oliveira ML et al. The Clavien-Dindo classification of surgical complications: five year experience. Annals of Surg 2002;250:187-96.
29. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-6.
30. Pentheroudakis G, Pappas P, Golfnopoloulos V et al. Weekday on-weekday off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. Cancer Chemother Pharmacol 2007;60:733-9.
31. Swellengrebel H A M, Marijnen C A M, Verwaal V et al. Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg 2011;98:418-26.
32. Das P, Eng C, Rodriguez-Bigas MA et al. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys 2014;88:301-5.
33. Dellas K, Buller J, Gorz GJ et al. Analysis of bevacizumabbased preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications. Ann Surg Oncol 2014;21:1352-60.
34. Mangoni M, Vozenin MC, Biti G et al. Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead. Br J Cancer 2012;107:308-14.